ValuEngine Downgrades Tetraphase Pharmaceuticals (TTPH) to Strong Sell

Tetraphase Pharmaceuticals (NASDAQ:TTPH) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued on Friday.

TTPH has been the subject of a number of other reports. Piper Jaffray Companies assumed coverage on Tetraphase Pharmaceuticals in a report on Monday, August 28th. They set an “overweight” rating and a $14.00 price objective for the company. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price target for the company in a research report on Saturday, September 23rd. Stifel Nicolaus reissued a “buy” rating and set a $13.00 price target on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, September 12th. Needham & Company LLC reissued a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Sunday, September 17th. Finally, BMO Capital Markets increased their price target on Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the company an “outperform” rating in a research report on Wednesday, October 4th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. Tetraphase Pharmaceuticals has an average rating of “Hold” and an average price target of $15.15.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) opened at $6.31 on Friday. Tetraphase Pharmaceuticals has a fifty-two week low of $3.57 and a fifty-two week high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.63). The business had revenue of $4.10 million during the quarter, compared to the consensus estimate of $1.59 million. Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. Tetraphase Pharmaceuticals’s quarterly revenue was up 355.6% on a year-over-year basis. During the same period last year, the company earned ($0.58) earnings per share. equities research analysts predict that Tetraphase Pharmaceuticals will post -2.88 EPS for the current year.

In other news, insider Jacques Dumas sold 8,750 shares of the firm’s stock in a transaction that occurred on Tuesday, October 31st. The stock was sold at an average price of $6.03, for a total value of $52,762.50. Following the completion of the sale, the insider now directly owns 8,750 shares of the company’s stock, valued at $52,762.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 5.50% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC acquired a new stake in shares of Tetraphase Pharmaceuticals in the third quarter valued at approximately $195,000. California State Teachers Retirement System lifted its position in shares of Tetraphase Pharmaceuticals by 20.1% in the third quarter. California State Teachers Retirement System now owns 80,471 shares of the biopharmaceutical company’s stock valued at $550,000 after buying an additional 13,451 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Tetraphase Pharmaceuticals by 32.7% in the third quarter. Dimensional Fund Advisors LP now owns 1,461,807 shares of the biopharmaceutical company’s stock valued at $9,998,000 after buying an additional 360,552 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Tetraphase Pharmaceuticals by 67.4% in the third quarter. Schwab Charles Investment Management Inc. now owns 217,079 shares of the biopharmaceutical company’s stock valued at $1,485,000 after buying an additional 87,398 shares during the last quarter. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Tetraphase Pharmaceuticals in the third quarter valued at approximately $7,915,000. 58.25% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/02/valuengine-downgrades-tetraphase-pharmaceuticals-ttph-to-strong-sell.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply